Infinity to Present at the Oppenheimer & Co. Annual Healthcare Conference

Rhea-AI Summary

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that its management will present at the Oppenheimer & Co. Annual Healthcare Conference from March 16-18, 2021. The presentation is scheduled for March 17 at 1:10 PM Eastern Time. Infinity is focused on developing eganelisib, an oral immuno-oncology therapeutic targeting immune suppression in cancer. The event can be accessed through a webcast available for 30 days post-event. For more on Infinity and eganelisib, visit www.infi.com.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that management will present at the Oppenheimer & Co. Annual Healthcare Conference which is being held Tuesday, March 16^th – Thursday, March 18^th, 2021. Presentation details are as follows:

Oppenheimer & Co. Annual Healthcare Conference Company Presentation:
Date:		Wednesday, March 17
Time:		1:10 pm Eastern Time
Webcast:		https://wsw.com/webcast/oppenheimer9/infi/2701886

The webcast of the presentation can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and eganelisib

Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil^® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.
Doxil^® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005164/en/

FAQ

What is the date and time of Infinity Pharmaceuticals' presentation at the Oppenheimer Conference?

Infinity Pharmaceuticals will present on March 17, 2021, at 1:10 PM Eastern Time.

How can I access the webcast for Infinity Pharmaceuticals' presentation?

The webcast can be accessed at https://wsw.com/webcast/oppenheimer9/infi/2701886.

What is eganelisib and its significance in oncology by Infinity Pharmaceuticals?

Eganelisib is a potential first-in-class oral immuno-oncology therapeutic that reprograms macrophages to combat immune suppression in cancer.

What studies is Infinity Pharmaceuticals conducting with eganelisib?

Infinity is conducting studies such as MARIO-275, MARIO-3, and a collaboration with Arcus Biosciences focusing on various cancer treatments.

Where can I find more information about Infinity Pharmaceuticals?

More information can be found on Infinity's website at www.infi.com.